Literature DB >> 1733746

Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy.

A M McGuire1, J S Duncan, M R Trimble.   

Abstract

Cognitive function and mood of patients with epilepsy who received 2 g/day vigabatrin (GVG) in addition to their usual antiepileptic drugs (AEDs) was assessed on two occasions: before start of treatment (baseline) and 4 weeks after start of treatment. A battery of selected psychological tasks measuring attention, mental speed, motor speed, central cognitive processing, and perceptuomotor performance was used, along with standardized, objective mood assessments. A comparison group (n = 15) of patients receiving stable medication was also tested to evaluate practice effects of the psychometric tests. Administration of 2 g/day GVG significantly decreased response time on a test of central cognitive processing ability (arithmetic). No adverse effect was noted on any other test of cognitive function or mood.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733746     DOI: 10.1111/j.1528-1157.1992.tb02295.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  13 in total

1.  The cognitive impact of antiepileptic drugs.

Authors:  Clare M Eddy; Hugh E Rickards; Andrea E Cavanna
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

Review 2.  The new antiepileptic drugs.

Authors:  R E Appleton
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

3.  Cognitive Adverse Effects of Antiepileptic Drugs : Incidence, Mechanisms and Therapeutic Implications.

Authors:  R Kälviäinen; M Äikiä; P J Riekkinen
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

Review 4.  Adverse reactions to new anticonvulsant drugs.

Authors:  I C Wong; S D Lhatoo
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 5.  Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors.

Authors:  Marco Mula; Michael R Trimble
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 6.  A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Authors:  J Srinivasan; A Richens
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

7.  Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy.

Authors:  R A Gillham; J Blacklaw; P J McKee; M J Brodie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-12       Impact factor: 10.154

8.  Effects of vigabatrin on partial seizures and cognitive function.

Authors:  R A Grünewald; P J Thompson; R Corcoran; Z Corden; G D Jackson; J S Duncan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

Review 9.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

10.  Treatment of refractory complex partial seizures: role of vigabatrin.

Authors:  Elizabeth J Waterhouse; Kimberly N Mims; Soundarya N Gowda
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.